	US 12,215,351 B2
	Methods for inducing hematopoietic stem cell specificity
Leonard I. Zon, Brookline, MA (US); and Joseph Mandelbaum, Boston, MA (US)
Assigned to THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US)
Appl. No. 16/640,403
Filed by THE CHILDREN'S MEDICAL CENTER CORPORATION, Boston, MA (US)
PCT Filed Aug. 21, 2018, PCT No. PCT/US2018/047242 § 371(c)(1), (2) Date Feb. 20, 2020, PCT Pub. No. WO2019/040448, PCT Pub. Date Feb. 28, 2019.
Claims priority of provisional application 62/548,436, filed on Aug. 22, 2017.
Prior Publication US 2020/0362308 A1, Nov. 19, 2020
Int. Cl. C12N 5/0789 (2010.01); A61K 31/404 (2006.01); A61K 31/426 (2006.01); A61K 31/444 (2006.01); A61K 31/5513 (2006.01); A61K 35/28 (2015.01); A61K 35/50 (2015.01); A61K 35/545 (2015.01); C12N 5/00 (2006.01)

CPC C12N 5/0647 (2013.01) [A61K 31/404 (2013.01); A61K 31/426 (2013.01); A61K 31/444 (2013.01); A61K 31/5513 (2013.01); A61K 35/50 (2013.01); A61K 35/545 (2013.01); C12N 5/0062 (2013.01); A61K 35/28 (2013.01); C12N 2501/999 (2013.01)]

12 Claims

1. A method for inducing hematopoietic stem cell (HSC) specification in a cell, the method comprising;

a) contacting a cell for a period of time with an agent selected from the group consisting of Ro5-3335, SU-5402, sc-221405, and AI-10; and

b) removing said agent after said period of time, thereby inducing HSC specification in the cell,

wherein the cell is selected from the group consisting of an hemogenic endothelial (HE) cell, an embryonic cell, an embryonic stem cell (ESC), a cell from a dissociated embryo, a cell from a dissociated embryo that is at least 9-hours post fertilization, an embryoid bodies, an induced pluripotent stem cell (iPSC), an aorta-gonad-mesonephros (AGM) cell, a placenta stem cell, an adult stem cell, and an amniotic stem cell,

wherein the concentration of the agent is greater than 2 μM.